Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PG286
- Development stage
- Preclinical
- Lead developer
- Alcon
- Administration
- Ophthalmic
01
Overview
PG286 is an investigational ophthalmic solution evaluated for its safety and ocular hypotensive efficacy. It has been studied in clinical trials as a topical treatment for lowering intraocular pressure, likely targeting conditions such as glaucoma or ocular hypertension. The drug has been compared to its individual components in clinical research, but detailed information about its mechanism of action, chemical class, or specific molecular target is not available from the provided sources[3].
- Other names
- PG286PG-286PG 286
Beyond the preview
Go deeper on PG286.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PG286.